instruction:-
Patient 1:
Malcolm is a 9-year-old male in the 4th grade at the public elementary school. Malcolm
has recently been diagnosed with ADHD, combined presentation. Malcolm struggles
with being fidgety and hyperactive; he often gets into trouble at school for blurting out
answers, getting out of his desk when he should not be, and hitting other children when
upset. Malcolm also needs help focusing on anything besides video games at
home. His parents report homework takes “all night,” though it should only take 30
minutes. Malcolm has assigned chores but often gets distracted. For example, Malcolm
was to take out the trash but got distracted in the driveway while taking out the garbage
and leaving the entire bag. He often misplaces the combination code for the
lock on the house door. This is my patient scenario.
Methylphenidate Con’s (this is my drug of choice).
In Week 5, you were assigned by the Faculty to argue either the pro (for) or con (against) for a particular medication. You were also provided information for a patient case study scenario. Week 5 was your opportunity to conduct research for this debate.
This week, you will present and defend your assigned stance (pro or con) and specific medication for your patient case study scenario with your peers. In the debate, you will also be able to share your perspective on why the alternative medication class would not be appropriate for the patient case scenario.
Please be sure to support your answers with evidence-based, peer-reviewed scholarly literature.
Note: APA style format with citations and references will apply.
As a reminder, these were the assigned medications:
Pro Con
Amphetamine
Amphetamine
Methylphenidate
Methylphenidate
Alpha Adrenergic Agonist
Alpha Adrenergic Agonist
Non-Stimulant
Non-Stimulant
resources:-
Goldin, D. S. (2023). Fast facts for psychopharmacology for nurse practitioners. Springer Publishing.
Chapter 9, “Stimulants/Neurodevelopmental Disorders” (pp. 178–208)
Chapter 10, “Antidementia” (pp. 208–227)
American Academy of Pediatrics. (2019, October). Clinical practice guidelines for diagnosing, evaluating, and treating attention-deficit/hyperactivity disorder in children and adolescents to an external site. Pediatrics, 144(4), Article e20192528. https://doi.org/10.1542/peds.2019-2528
Drugs.comLinks to an external site.. (2023). https://www.drugs.com/
Note: Please use the following resource to check the most up-to-date box warnings, FDA approvals and indications, recommendations for follow-up evaluations, changes, etc.
CHADD’s National Resource Center on ADHD. (2023). ADHD medications approved by the U.S. Food and Drug Administration: Stimulant medications. https://d393uh8gb46l22.cloudfront.net/wp-content/uploads/2020/02/ADHD-Medications-Approved-by-FDA-2.23.pdf
Note: Utilize this medication table resource to familiarize yourself with the medications aligned with the topics presented this week.
